ROCKVILLE, Maryland - 1 December 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announcesthat pursuant to its block admission facility, since 31 October 2023 it has issued133,442of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.
ROCKVILLE, MD, November 30, 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 27 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, aNon-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
ROCKVILLE, MD, November 17, 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 14 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, aNon-Executive Director of the Company, exercised options over 10,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines ROCKVILLE, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 7079T MaxCyte, Inc. 16 November 2023 MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines.
RNS Number : 8538S MaxCyte, Inc. 09 November 2023 MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2023 ROCKVILLE, MD , November 9, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 8496S MaxCyte, Inc. 09 November 2023 MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD , November 9, 2023 Ñ MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 5574S MaxCyte, Inc. 07 November 2023 MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD , November 7, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
